Published in J Exp Med on November 17, 2003
Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet (2009) 4.56
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med (2009) 2.56
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med (2009) 2.43
Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J Exp Med (2004) 2.04
Advanced glycation end product recognition by the receptor for AGEs. Structure (2011) 1.84
The receptor for advanced glycation end products (RAGE) and the lung. J Biomed Biotechnol (2010) 1.68
HMGB1 in health and disease. Mol Aspects Med (2014) 1.67
Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response. J Mol Med (Berl) (2009) 1.51
Leukocyte-endothelial interactions in inflammation. J Cell Mol Med (2009) 1.51
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection. Crit Care (2007) 1.50
Retracted The effect of soluble RAGE on inhibition of angiotensin II-mediated atherosclerosis in apolipoprotein E deficient mice. PLoS One (2013) 1.47
AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol (2009) 1.45
Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther (2005) 1.43
RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol (2008) 1.41
Role of advanced glycation end products in cellular signaling. Redox Biol (2014) 1.36
RAGE signaling in inflammation and arterial aging. Front Biosci (Landmark Ed) (2009) 1.35
The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med (2009) 1.35
Bench-to-bedside review: The inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care (2008) 1.34
RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation? J Alzheimers Dis (2009) 1.31
Microvascular responses to cardiovascular risk factors. Microcirculation (2010) 1.30
Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol (2008) 1.30
Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab (2013) 1.30
Tempering the wrath of RAGE: an emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation. Ann Med (2009) 1.25
Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules (2015) 1.23
HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE. J Bone Miner Res (2008) 1.23
Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflam (2013) 1.22
Regulation of osteoclast function and bone mass by RAGE. J Exp Med (2006) 1.21
The receptor RAGE: Bridging inflammation and cancer. Cell Commun Signal (2009) 1.20
Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J Biol Chem (2010) 1.19
Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus. J Exp Med (2006) 1.17
Microglia function in Alzheimer's disease. Front Pharmacol (2012) 1.17
Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci (2008) 1.17
Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci (2013) 1.15
Plasma sRAGE enables prediction of acute lung injury after cardiac surgery in children. Crit Care (2012) 1.15
Advanced glycation end products are direct modulators of β-cell function. Diabetes (2011) 1.14
The innate immune system in allograft rejection and tolerance. J Immunol (2007) 1.13
Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood (2005) 1.13
Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am J Pathol (2006) 1.13
Role of advanced glycation end products in cardiovascular disease. World J Cardiol (2012) 1.13
The diverse ligand repertoire of the receptor for advanced glycation endproducts and pathways to the complications of diabetes. Vascul Pharmacol (2012) 1.12
Novel aspects in the regulation of the leukocyte adhesion cascade. Thromb Haemost (2009) 1.11
RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med (2007) 1.11
Regulation of LFA-1-dependent inflammatory cell recruitment by Cbl-b and 14-3-3 proteins. Blood (2008) 1.10
Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther (2014) 1.08
The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms. Blood (2005) 1.07
Rho GTPases and leucocyte-induced endothelial remodelling. Biochem J (2005) 1.07
RAGE regulates the metabolic and inflammatory response to high-fat feeding in mice. Diabetes (2014) 1.05
The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation. PLoS Pathog (2011) 1.05
RAGE: a new frontier in chronic airways disease. Br J Pharmacol (2012) 1.04
The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry (2014) 1.02
Binding of CD40L to Mac-1's I-domain involves the EQLKKSKTL motif and mediates leukocyte recruitment and atherosclerosis--but does not affect immunity and thrombosis in mice. Circ Res (2011) 1.01
Receptor for advanced glycation end products (RAGE) prevents endothelial cell membrane resealing and regulates F-actin remodeling in a beta-catenin-dependent manner. J Biol Chem (2011) 1.01
Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol (2008) 1.00
Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2. Diabetes (2012) 0.98
Mechanisms of neutrophil transendothelial migration. Front Biosci (Landmark Ed) (2009) 0.98
Maturation-induced down-regulation of MFG-E8 impairs apoptotic cell clearance and enhances endotoxin response. Int J Mol Med (2008) 0.97
Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp Diabetes Res (2011) 0.97
Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3. Proc Natl Acad Sci U S A (2013) 0.95
APPswe/Aβ regulation of osteoclast activation and RAGE expression in an age-dependent manner. J Bone Miner Res (2011) 0.94
Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE. J Matern Fetal Neonatal Med (2012) 0.94
Uremic Toxicity of Advanced Glycation End Products in CKD. J Am Soc Nephrol (2015) 0.94
S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clin Cancer Res (2012) 0.93
The role of receptor for advanced glycation endproducts (RAGE) in infection. Crit Care (2011) 0.92
Oligomerization interface of RAGE receptor revealed by MS-monitored hydrogen deuterium exchange. PLoS One (2013) 0.91
Soluble RAGE: a hot new biomarker for the hot joint? Arthritis Res Ther (2005) 0.90
Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea. PLoS One (2011) 0.90
RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. Diabetes (2012) 0.89
RAGE and ICAM-1 differentially control leukocyte recruitment during acute inflammation in a stimulus-dependent manner. BMC Immunol (2011) 0.88
Differential activation of RAGE by HMGB1 modulates neutrophil-associated NADPH oxidase activity and bacterial killing. Am J Physiol Cell Physiol (2011) 0.87
Associations between maternal and infant morbidities and sRAGE within the first week of life in extremely preterm infants. PLoS One (2013) 0.87
The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant. J Biol Chem (2011) 0.87
Downregulation of an astrocyte-derived inflammatory protein, S100B, reduces vascular inflammatory responses in brains persistently infected with Borna disease virus. J Virol (2007) 0.87
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. Int J Mol Sci (2013) 0.86
GM-CSF production by glioblastoma cells has a functional role in eosinophil survival, activation, and growth factor production for enhanced tumor cell proliferation. J Immunol (2011) 0.86
The role of proteomics in the diagnosis of chorioamnionitis and early-onset neonatal sepsis. Clin Perinatol (2010) 0.86
Is RAGE still a therapeutic target for Alzheimer's disease? Future Med Chem (2012) 0.86
Pulmonary receptor for advanced glycation end-products promotes asthma pathogenesis through IL-33 and accumulation of group 2 innate lymphoid cells. J Allergy Clin Immunol (2015) 0.85
Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression. Biochem J (2006) 0.85
A role of kindlin-3 in integrin αMβ2 outside-in signaling and the Syk-Vav1-Rac1/Cdc42 signaling axis. PLoS One (2013) 0.85
Longistatin in tick saliva blocks advanced glycation end-product receptor activation. J Clin Invest (2014) 0.85
Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Clin Pharmacol Ther (2015) 0.85
The novel RAGE interactor PRAK is associated with autophagy signaling in Alzheimer's disease pathogenesis. Mol Neurodegener (2016) 0.85
RAGE regulates immune cell infiltration and angiogenesis in choroidal neovascularization. PLoS One (2014) 0.84
Cellular and Molecular Mechanisms of Chronic Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities. Front Immunol (2015) 0.84
Inhibitory effect of receptor for advanced glycation end products (RAGE) on the TGF-β-induced alveolar epithelial to mesenchymal transition. Exp Mol Med (2011) 0.84
Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure. Curr Heart Fail Rep (2012) 0.84
RAGE and its ligands in bone metabolism. Front Biosci (Schol Ed) (2011) 0.83
Disulfide bonds within the C2 domain of RAGE play key roles in its dimerization and biogenesis. PLoS One (2012) 0.83
Decreased levels of soluble receptor for advanced glycation end products in patients with primary Sjögren's syndrome. Rheumatol Int (2008) 0.82
Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection. J Infect Dis (2012) 0.81
Reactive astrocytes promote adhesive interactions between brain endothelium and endothelial progenitor cells via HMGB1 and beta-2 integrin signaling. Stem Cell Res (2013) 0.81
Estrogen replacement therapy in diabetic ovariectomized female rats potentiates postischemic leukocyte adhesion in cerebral venules via a RAGE-related process. Am J Physiol Heart Circ Physiol (2009) 0.81
Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications. J Diabetes Investig (2012) 0.81
Extracellular high-mobility group box 1 is increased in patients with Behçet's disease with intestinal involvement. J Korean Med Sci (2011) 0.81
S100A9 induced inflammatory responses are mediated by distinct damage associated molecular patterns (DAMP) receptors in vitro and in vivo. PLoS One (2015) 0.80
The Streptococcus pyogenes NAD(+) glycohydrolase modulates epithelial cell PARylation and HMGB1 release. Cell Microbiol (2015) 0.79
RAGE controls activation and anti-inflammatory signalling of protein C. PLoS One (2014) 0.79
Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell (1994) 27.85
Leukocyte-endothelial adhesion molecules. Blood (1994) 8.62
RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell (1999) 8.55
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature (2000) 6.70
Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med (1998) 5.54
The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest (2001) 5.49
Ligand binding to integrins. J Biol Chem (2000) 4.94
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation (2002) 3.93
Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes (2001) 3.83
N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem (1999) 3.72
Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem (1992) 3.64
Inflammatory and immune responses are impaired in mice deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci U S A (1993) 3.57
Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis (2001) 3.06
Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem (1997) 2.66
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med (2002) 2.42
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol (2001) 2.33
Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest (1996) 2.03
Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J Clin Invest (1993) 1.99
Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat Med (2002) 1.92
The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol (1998) 1.91
Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A (1994) 1.85
Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood (1998) 1.81
Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol (2001) 1.64
Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation (1997) 1.38
Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol (1997) 1.16
Regulation of leukocyte recruitment by polypeptides derived from high molecular weight kininogen. FASEB J (2001) 1.05
Expression efficiency of the human thrombomodulin-encoding gene in various vector and host systems. Gene (1994) 0.99
Different mechanisms define the antiadhesive function of high molecular weight kininogen in integrin- and urokinase receptor-dependent interactions. Blood (2000) 0.99
Molecular mechanisms of zinc-dependent leukocyte adhesion involving the urokinase receptor and beta2-integrins. Blood (1999) 0.98
Leukocyte trans-endothelial migration: JAMs add new pieces to the puzzle. Thromb Haemost (2003) 0.95
Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol (2007) 8.33
Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med (2006) 5.49
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) (2005) 4.96
Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians' diagnoses. J Affect Disord (2004) 4.64
Acupuncture and knee osteoarthritis: a three-armed randomized trial. Ann Intern Med (2006) 4.42
Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med (2010) 4.32
Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest (2004) 3.89
A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A (2003) 3.82
A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A (2010) 3.80
Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med (2012) 3.63
High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation (2008) 3.46
Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A (2007) 3.36
Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med (2007) 3.35
Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med (2012) 3.31
Neutrophil extracellular traps directly induce epithelial and endothelial cell death: a predominant role of histones. PLoS One (2012) 3.13
Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature (2008) 3.05
Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol (2005) 3.05
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med (2003) 2.61
Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial. Stroke (2007) 2.56
RAGE signaling sustains inflammation and promotes tumor development. J Exp Med (2008) 2.51
Enolase-1 promotes plasminogen-mediated recruitment of monocytes to the acutely inflamed lung. Blood (2009) 2.50
A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J (2007) 2.44
RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol (2003) 2.43
The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J Exp Med (2002) 2.42
Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes (2008) 2.41
Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest (2003) 2.40
Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res (2002) 2.35
RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis (2008) 2.33
Atherogenic dyslipidaemia but not total- and high-molecular weight adiponectin are associated with the prognostic outcome in patients with coronary heart disease. Eur Heart J (2008) 2.26
Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock (2009) 2.26
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis. Crit Care Med (2008) 2.18
Role of extracellular RNA in atherosclerotic plaque formation in mice. Circulation (2013) 2.18
A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol (2008) 2.17
Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res (2010) 2.02
Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci U S A (2005) 1.97
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest (2009) 1.96
Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat Med (2002) 1.92
Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest (2004) 1.92
Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care (2012) 1.90
The junctional adhesion molecule-C promotes neutrophil transendothelial migration in vitro and in vivo. J Biol Chem (2004) 1.89
Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. Proc Natl Acad Sci U S A (2005) 1.84
Low but sustained coagulation activation ameliorates glucose-induced podocyte apoptosis: protective effect of factor V Leiden in diabetic nephropathy. Blood (2011) 1.83
Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell (2008) 1.81
Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood (2004) 1.77
Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem (2006) 1.75
Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 1.75
RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol (2009) 1.72
RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microbes Infect (2004) 1.63
Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis. J Clin Invest (2011) 1.63
Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int (2011) 1.63
Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care (2005) 1.62
Surgical versus medical treatment of type 2 diabetes mellitus in nonseverely obese patients: a systematic review and meta-analysis. Ann Surg (2015) 1.62
Diagnosing ICD-10 depressive episodes: superior criterion validity of the Patient Health Questionnaire. Psychother Psychosom (2004) 1.59
Detecting panic disorder in medical and psychosomatic outpatients: comparative validation of the Hospital Anxiety and Depression Scale, the Patient Health Questionnaire, a screening question, and physicians' diagnosis. J Psychosom Res (2003) 1.58
Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol (2003) 1.57
A system for the construction of targeted unmarked gene deletions in the genus Burkholderia. Environ Microbiol (2008) 1.57
Complex formation with nucleic acids and aptamers alters the antigenic properties of platelet factor 4. Blood (2013) 1.56
Extracellular RNA promotes leukocyte recruitment in the vascular system by mobilising proinflammatory cytokines. Thromb Haemost (2012) 1.55
Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. Respir Med (2010) 1.54
The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31). J Biol Chem (2007) 1.53
Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem (2008) 1.52
RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol (2002) 1.52
sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res (2007) 1.47
AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol (2009) 1.45
C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes (2009) 1.45
The Case: Renal failure in a male with Waldenström's macroglobulinemia. Kidney Int (2010) 1.44
Evidence of left ventricular contractile asynchrony by echocardiographic phase imaging in patients with type 2 diabetes mellitus and without clinically evident heart disease. Am J Cardiol (2006) 1.44